Melanoma News

CancerConnect melanoma news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of melanoma research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of melanoma treatment and survivorship.

Share

Melanoma News


Nivolumab Superior to Chemotherapy in First Phase III Trial as Initial Treatment in Advanced Melanoma (November 20, 2014)

The immunotherapy drug nivolumab produces significantly better overall survival than chemotherapy as initial treatment in advanced melanoma, according to findings from its first Phase III study in previously... Continue Reading

Thin Melanomas Responsible for Many Melanoma Related Deaths (November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to... Continue Reading

MRA Applauds Congress for Getting the Sunscreen Innovation Act over the Goal Line (November 17, 2014)

(OMNI-CancerConnect) — The Melanoma Research Alliance (MRA) applauds the House for acting on the Senate-passed Sunscreen Innovation Act, clearing the way for the President’s signature. Thanks to the... Continue Reading

Progress in the Treatment of Advanced Melanoma and Other Skin Cancers (November 14, 2014)

Online Melanoma Support Group By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society,... Continue Reading

Immune Booster Combined with Checkpoint Blocker Improves Survival in Metastatic Melanoma (November 12, 2014)

Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received... Continue Reading

Targeted Therapy Nivolumab Outperforms Chemotherapy in Advanced Melanoma (October 13, 2014)

Nivolumab appears to be more active and safer than chemotherapy in patients with advanced melanoma who have received previous treatment. These findings were presented at the 2014 European Society for Medical... Continue Reading

COMBI-v BRAF/MEK Inhibitor Combination Trial Impressive in Melanoma (October 8, 2014)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the... Continue Reading

BRAF/MEK Inhibitor Combination Impressive in Melanoma Trials (October 2, 2014)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the... Continue Reading

Pembrolizumab Gets FDA Approval in Advanced Melanoma (September 5, 2014)

The U.S. Food & Drug Administration (FDA) has granted approval to Merck’s new immunotherapy drug, Keytruda (pembrolizumab), for treating metastatic melanoma.   It is the first anti-PD-1 drug, aimed... Continue Reading

OMNI-Connect Gets National Recognition as Valuable Social Media Solution in Medicine (August 13, 2014)

Fort Worth TX/Sun Valley ID – OMNI Health Media announces national recognition of its online support communities, TheGIConnection,TheRAConnection, and Cancer Connect, as valuable resources for... Continue Reading

More Melanoma News

Latest Melanoma News By Stage


Screening/Prevention

Thin Melanomas Responsible for Many Melanoma Related Deaths (November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to be more dangerous. Researchers in Australia wanted... Continue Reading

MRA Applauds Congress for Getting the Sunscreen Innovation Act over the Goal Line (November 17, 2014)

(OMNI-CancerConnect) — The Melanoma Research Alliance (MRA) applauds the House for acting on the Senate-passed Sunscreen Innovation Act, clearing the way for the President’s signature. Thanks to the leadership and hard work of Congressmen Ed Whitfield... Continue Reading

May Is National Skin Cancer Detection and Prevention Month (May 1, 2014)

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of skin cancer programs for national skin cancer detection and prevention month. As the month of May brings skin cancer into focus, it’s time to increase public understanding... Continue Reading

Viagra Associated with Increased Risk of Melanoma (April 18, 2014)

Men who take by Viagra (sildenafil) are 84 percent more likely to develop melanoma than men who do not, according to the results of a study published in JAMA Internal Medicine. Melanoma is a potentially fatal type of skin cancer that begins in the melanocytes,... Continue Reading

Aspirin Reduces Risk of Melanoma in Women (March 20, 2013)

Women who regularly take aspirin have a reduced risk of developing melanoma, according to the results of a study published in Cancer.[1] What’s more—the longer they take the aspirin, the lower the risk. Of the more than one million new diagnoses of... Continue Reading

More Screening and Prevention

Stages I-II

Thin Melanomas Responsible for Many Melanoma Related Deaths (November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to be more dangerous. Researchers in Australia wanted... Continue Reading

Melanoma More Deadly in Young White Men than Women (August 12, 2013)

Adolescent and young white men with melanoma are more than 50 percent more likely than their female counterparts to die from the disease, according to the results of a study published in JAMA Dermatology.[1] Melanoma is a deadly type of skin cancer that... Continue Reading

Lymphoseek Approved for Detecting Lymph Nodes in Breast Cancer and Melanoma (April 10, 2013)

The U.S. Food and Drug Administration (FDA) has approved Lymphoseek® (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing... Continue Reading

Adjuvant Radiotherapy for the Management of High-Risk Malignant Melanoma (September 24, 2012)

Adjuvant radiotherapy significantly improved regional lymphatic control for high-risk patients after therapeutic lymphadenectomy for metastatic melanoma, according to the results of a study published in the Lancet Oncology. Of the more than one million... Continue Reading

Women More Likely to Survive Melanoma Than Men (May 16, 2012)

Women are 30 percent more likely to survive melanoma than men, according to the results of a study published in the Journal of Clinical Oncology.[1] Melanoma is a deadly type of skin cancer that arises from melanocytes, which are cells located in the... Continue Reading

More Stages I-II

Stage III

Progress in the Treatment of Advanced Melanoma and Other Skin Cancers (November 14, 2014)

Online Melanoma Support Group By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society, 3.5 million cases of basal and squamous cell skin... Continue Reading

COMBI-v BRAF/MEK Inhibitor Combination Trial Impressive in Melanoma (October 8, 2014)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the more than one million new diagnoses of skin cancer... Continue Reading

BRAF/MEK Inhibitor Combination Impressive in Melanoma Trials (October 2, 2014)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the more than one million new diagnoses of skin cancer... Continue Reading

Largest Study to Date of Pembrolizumab in Advanced Melanoma Shows Promising Activity (July 31, 2014)

The investigational anti-PD-1 antibody pembrolizumab is demonstrating promising survival rates among patients with advanced melanoma. Data from an ongoing Phase 1 trial of the drug were presented at the 50th Annual Meeting of the American Society of Clinical... Continue Reading

Investigational Drug Pembrolizumab Shows Anticancer Activity in Advanced Melanoma (July 30, 2014)

Recent findings reported in The Lancet indicate that the investigational drug pembrolizumab may be effective in patients with advanced melanoma that has progressed after treatment with Yervoy® (ipilimumab).[1] These findings build on previous research... Continue Reading

More Stage III

Stage IV

Nivolumab Superior to Chemotherapy in First Phase III Trial as Initial Treatment in Advanced Melanoma (November 20, 2014)

The immunotherapy drug nivolumab produces significantly better overall survival than chemotherapy as initial treatment in advanced melanoma, according to findings from its first Phase III study in previously untreated patients. These results were recently... Continue Reading

Progress in the Treatment of Advanced Melanoma and Other Skin Cancers (November 14, 2014)

Online Melanoma Support Group By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society, 3.5 million cases of basal and squamous cell skin... Continue Reading

Immune Booster Combined with Checkpoint Blocker Improves Survival in Metastatic Melanoma (November 12, 2014)

Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant, according to a study led by... Continue Reading

Targeted Therapy Nivolumab Outperforms Chemotherapy in Advanced Melanoma (October 13, 2014)

Nivolumab appears to be more active and safer than chemotherapy in patients with advanced melanoma who have received previous treatment. These findings were presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain,... Continue Reading

COMBI-v BRAF/MEK Inhibitor Combination Trial Impressive in Melanoma (October 8, 2014)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the more than one million new diagnoses of skin cancer... Continue Reading

More Stage IV

Recurrent

Nivolumab Superior to Chemotherapy in First Phase III Trial as Initial Treatment in Advanced Melanoma (November 20, 2014)

The immunotherapy drug nivolumab produces significantly better overall survival than chemotherapy as initial treatment in advanced melanoma, according to findings from its first Phase III study in previously untreated patients. These results were recently... Continue Reading

Thin Melanomas Responsible for Many Melanoma Related Deaths (November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to be more dangerous. Researchers in Australia wanted... Continue Reading

Progress in the Treatment of Advanced Melanoma and Other Skin Cancers (November 14, 2014)

Online Melanoma Support Group By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society, 3.5 million cases of basal and squamous cell skin... Continue Reading

Immune Booster Combined with Checkpoint Blocker Improves Survival in Metastatic Melanoma (November 12, 2014)

Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant, according to a study led by... Continue Reading

Targeted Therapy Nivolumab Outperforms Chemotherapy in Advanced Melanoma (October 13, 2014)

Nivolumab appears to be more active and safer than chemotherapy in patients with advanced melanoma who have received previous treatment. These findings were presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain,... Continue Reading

More Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Just another WordPress weblog
Facebook Twitter RSS